2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses some of the ongoing challenges in the treatment of patients with multiple myeloma.
Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses some of the ongoing challenges in the treatment of patients with multiple myeloma.
There are many challenges that oncologists are still facing in this field, including the fact that there is not a 100% cure rate, Jackson explains. There are a lot of patients with durable responses who have low-risk disease; however, for patients with high-risk disease who go through treatment lines very quickly, they are mostly transient responses, leading researchers to believe that this subpopulation is a higher unmet need.
Additionally, patients become refractory to several therapies. Results of the STORM study, which explored selinexor (KPT-330) in this population of patients, are intriguing, he adds. Novel agents moving through the pipeline are likely to lead excitement in the field.
Related Content: